title: Radiofrequency ablation of renal tumors in the solitary kidney.
abstract: OBJECTIVE
  Radiofrequency ablation (RFA) is a minimally invasive therapy aimed at maximal preservation of renal function in the nonsurgical renal mass patient. We evaluate our experience with RFA of renal tumors in the solitary kidney.
  
  
  METHODS
  A retrospective review of all patients with a solitary kidney treated with RFA for renal mass was performed. Two radiologists reviewed all images. From December 2001 to June 2006, 55 renal tumors were treated with RFA in 30 patients with a solitary kidney. Percutaneous approach was used in 44 tumors (26 patients) and intraoperative open approach in 11 tumors (4 patients). Average mass size was 2.0 cm (1.2-5.4). Biopsy performed prior to ablation in 14 tumors showed renal cell carcinoma in 12 (86%) and was non diagnostic in 2 (14%).
  
  
  RESULTS
  There were no major post procedural complications. Initial technical success was noted in 98% of tumors in 97% of patients. Average follow-up with contrast enhanced CT or MRI was 25 months (3-47) in 26 patients (50 tumors) and showed local tumor control in 100%. No difference in preoperative and postoperative calculated creatinine clearance was noted (p = 0.072). There was no difference in systolic (p = 0.102) and diastolic (p = 0.790) blood pressure pre and post ablation.
  
  
  CONCLUSIONS
  RFA of renal masses in the solitary kidney appears to be a safe, minimally invasive alternative to open surgical resection in properly selected patients. Local tumor control was achieved with no adverse effects on renal function and blood pressure in this series.
authors.affiliation: Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: Amy E
authors.initials: AE
authors.lastname: Krambeck
authors.forename: Michael A
authors.initials: MA
authors.lastname: Farrell
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Callstrom
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Atwell
authors.forename: J William
authors.initials: JW
authors.lastname: Charboneau
authors.forename: George K
authors.initials: GK
authors.lastname: Chow
authors.forename: David S
authors.initials: DS
authors.lastname: Dimarco
authors.forename: David E
authors.initials: DE
authors.lastname: Patterson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery; D017115:Catheter Ablation / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D007668:Kidney / Q000002:abnormalities* / Q000503:physiopathology / Q000601:surgery; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome